RATIONALE: The positive modulation of gamma-aminobutyric acid type-A (GABAA) receptors is a putative mechanism via which alcohol escalates aggressive behavior. Broad-spectrum benzodiazepine antagonists block alcohol-heightened aggression in rats and monkeys. However, the degree to which GABAA subunit composition plays a role in heightened aggressive behavior induced by self-administration of a moderate alcohol dose remains unresolved. OBJECTIVE: Beta-carboline-3-carboxylate-t-butyl ester (beta-CCt) and zolpidem act preferentially at GABAA receptors containing the alpha1 subunit as antagonist and agonist, respectively, and serve as useful tools to evaluate the role of GABAA receptor subtypes in self-administered alcohol on aggression. METHODS: Male resident mice, housed in breeding pairs, were conditioned to nose-poke in a removable panel in their home cage, with each fifth poke being reinforced by the delivery of 0.05 ml of 6% ethanol (EtOH). After consuming EtOH, the resident mice were given the antagonists beta-CCt and flumazenil or agonists zolpidem and triazolam, and then confronted an intruder male in their home cage for a 5-min period. RESULTS: Following self-administration of EtOH (1.0 g/kg, 1.7 g/kg), 14 of 37 resident mice displayed unusually large increases in the frequency of attack bites and sideways threats. Flumazenil or beta-CCt decreased alcohol-heightened and non-heightened aggression in a dose-dependent manner. Administration of 3 mg/kg beta-CCt lowered the aggression-heightening effects of 1 g/kg and 1.7 g/kg EtOH, but did not antagonize the sedative effects of 3.0 g/kg EtOH. Triazolam and zolpidem decreased alcohol-heightened and non-heightened aggressive behavior, and these antiaggressive effects were accompanied by reduced motor activity, indicating sedation. CONCLUSIONS: Benzodiazepine antagonists, particularly those acting preferentially at GABAA/alpha1 subunit-containing receptors, decrease alcohol-heightened and species-typical aggressive behavior, but are ineffective in attenuating the sedative effects of alcohol.
RATIONALE: The positive modulation of gamma-aminobutyric acid type-A (GABAA) receptors is a putative mechanism via which alcohol escalates aggressive behavior. Broad-spectrum benzodiazepine antagonists block alcohol-heightened aggression in rats and monkeys. However, the degree to which GABAA subunit composition plays a role in heightened aggressive behavior induced by self-administration of a moderate alcohol dose remains unresolved. OBJECTIVE:Beta-carboline-3-carboxylate-t-butyl ester (beta-CCt) and zolpidem act preferentially at GABAA receptors containing the alpha1 subunit as antagonist and agonist, respectively, and serve as useful tools to evaluate the role of GABAA receptor subtypes in self-administered alcohol on aggression. METHODS: Male resident mice, housed in breeding pairs, were conditioned to nose-poke in a removable panel in their home cage, with each fifth poke being reinforced by the delivery of 0.05 ml of 6% ethanol (EtOH). After consuming EtOH, the resident mice were given the antagonists beta-CCt and flumazenil or agonists zolpidem and triazolam, and then confronted an intruder male in their home cage for a 5-min period. RESULTS: Following self-administration of EtOH (1.0 g/kg, 1.7 g/kg), 14 of 37 resident mice displayed unusually large increases in the frequency of attack bites and sideways threats. Flumazenil or beta-CCt decreased alcohol-heightened and non-heightened aggression in a dose-dependent manner. Administration of 3 mg/kg beta-CCt lowered the aggression-heightening effects of 1 g/kg and 1.7 g/kg EtOH, but did not antagonize the sedative effects of 3.0 g/kg EtOH. Triazolam and zolpidem decreased alcohol-heightened and non-heightened aggressive behavior, and these antiaggressive effects were accompanied by reduced motor activity, indicating sedation. CONCLUSIONS:Benzodiazepine antagonists, particularly those acting preferentially at GABAA/alpha1 subunit-containing receptors, decrease alcohol-heightened and species-typical aggressive behavior, but are ineffective in attenuating the sedative effects of alcohol.
Authors: K Löw; F Crestani; R Keist; D Benke; I Brünig; J A Benson; J M Fritschy; T Rülicke; H Bluethmann; H Möhler; U Rudolph Journal: Science Date: 2000-10-06 Impact factor: 47.728
Authors: H L June; S C Harvey; K L Foster; P F McKay; R Cummings; M Garcia; D Mason; C Grey; S McCane; L S Williams; T B Johnson; X He; S Rock; J M Cook Journal: J Neurosci Date: 2001-03-15 Impact factor: 6.167
Authors: James K Rowlett; Roger D Spealman; Snjezana Lelas; James M Cook; Wenyuan Yin Journal: Psychopharmacology (Berl) Date: 2002-11-06 Impact factor: 4.530
Authors: Klaus A Miczek; Naz Akdilek; Vania M M Ferreira; Michael Z Leonard; Lillian R Marinelli; Herbert E Covington Journal: Psychopharmacology (Berl) Date: 2022-08-11 Impact factor: 4.415
Authors: Klaus A Miczek; Joseph F DeBold; Lara S Hwa; Emily L Newman; Rosa M M de Almeida Journal: Ann N Y Acad Sci Date: 2015-08-18 Impact factor: 5.691
Authors: Shannon L Gourley; Joseph F Debold; Wenyuan Yin; James Cook; Klaus A Miczek Journal: Psychopharmacology (Berl) Date: 2004-08-17 Impact factor: 4.530
Authors: Sandeep Kumar; Patrizia Porcu; David F Werner; Douglas B Matthews; Jaime L Diaz-Granados; Rebecca S Helfand; A Leslie Morrow Journal: Psychopharmacology (Berl) Date: 2009-05-20 Impact factor: 4.530
Authors: Rosa Maria M de Almeida; Quelin Benini; Juliana S Betat; Débora C Hipólide; Klaus A Miczek; Anders I Svensson Journal: Psychopharmacology (Berl) Date: 2007-12-14 Impact factor: 4.415